{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:48:40Z","timestamp":1777132120882,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.amjcard.2023.07.154","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:47:43Z","timestamp":1692708463000},"page":"259-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Angiotensin Receptor\u2013Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4312-4172","authenticated-orcid":false,"given":"Lis Victoria","family":"Ravani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas Mesadri","family":"Gewehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Calomeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateus de Miranda","family":"Gauza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jussara","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhanderson","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique Barbosa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edimar","family":"Bocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2023.07.154_bib0001","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0003","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3389\/fphys.2020.01067","article-title":"Role of renin-angiotensin system components in atherosclerosis: focus on Ang-II, ACE2, and Ang-1\u20137","volume":"11","author":"Silva","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0004","doi-asserted-by":"crossref","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","article-title":"Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system","volume":"292","author":"Mehta","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0005","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1038\/s41598-019-42994-1","article-title":"Neprilysin inhibitor\u2013angiotensin II receptor blocker combination therapy (Sacubitril\/valsartan) suppresses atherosclerotic plaque formation and inhibits inflammation in apolipoprotein E- deficient mice","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0006","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5551\/jat.14266","article-title":"Plaque-stabilizing effect of angiotensin-converting enzyme inhibitor and\/or angiotensin receptor blocker in a rabbit plaque model","volume":"20","author":"Hotchi","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0007","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0008","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin Inhibition versus enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0009","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0010","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022)","author":"Higgins","year":"2022"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0011","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0012","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/eb-2018-102911","article-title":"Practical guide to the meta-analysis of rare events","volume":"21","author":"Efthimiou","year":"2018","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0013","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0014","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/eb-2013-101699","article-title":"How to assess publication bias: funnel plot, trim-and-fill method and selection models","volume":"17","author":"Mavridis","year":"2014","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0016","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","author":"Balduzzi","year":"2019","journal-title":"Evidence-Based Mental Health"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0017","first-page":"36","article-title":"Conducting Meta-Analyses in R with the metafor Package","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0018","unstructured":"Harrer M, Cuijpers P, Furukawa T, Ebert DD. Dmetar: Companion R Package for the Guide \u201cDoing Meta-Analysis in R\u201d. R Package Version 0.0.9000; 2019. Available at: http:\/\/dmetar.protectlab.org\/. Accessed on January 10, 2023."},{"key":"10.1016\/j.amjcard.2023.07.154_bib0019","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0020","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1002\/ejhf.2355","article-title":"A randomized clinical trial on the short-term effects of 12-week sacubitril\/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study","volume":"23","author":"Halle","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0021","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0022","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40256-020-00440-y","article-title":"The AWAKE-HF study: Sacubitril\/Valsartan impact on daily physical activity and sleep in heart failure","volume":"21","author":"Khandwalla","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ejhf.2076","article-title":"OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction","volume":"23","author":"Piepoli","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0024","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0025","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of Sacubitril\/Valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0026","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ahj.2017.02.034","article-title":"The effects of sacubitril\/valsartan on coronary outcomes in PARADIGM-HF","volume":"188","author":"Mogensen","year":"2017","journal-title":"Am Heart J"},{"issue":"20","key":"10.1016\/j.amjcard.2023.07.154_bib0027","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor\u2013neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0028","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with Sacubitril\/Valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0029","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1152\/japplphysiol.00454.2020","article-title":"Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction","volume":"130","author":"Bunsawat","year":"2021","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.amjcard.2023.07.154_bib0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13643-018-0726-5","article-title":"Does information from ClinicalTrials.gov increase transparency and reduce bias? Results from a five-report case series","volume":"7","author":"Adam","year":"2018","journal-title":"ClinicalTrials.gov. Syst Rev"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923007245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923007245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:49:59Z","timestamp":1757573399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914923007245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":30,"alternative-id":["S0002914923007245"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.154","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin Receptor\u2013Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}